Peel Hunt reissued their buy rating on shares of Puretech Health PLC (LON:PRTC) in a report released on Monday morning, StockTargetPrices.com reports. The brokerage currently has a GBX 278 ($3.66) price objective on the stock.
PRTC has been the topic of several other reports. Numis Securities Ltd reaffirmed a buy rating and set a GBX 207 ($2.72) price objective on shares of Puretech Health PLC in a report on Monday, September 25th. Liberum Capital reaffirmed a buy rating and set a GBX 248 ($3.26) price objective on shares of Puretech Health PLC in a report on Wednesday, July 12th. Jefferies Group LLC reaffirmed a buy rating and set a GBX 225 ($2.96) price objective on shares of Puretech Health PLC in a report on Wednesday, August 30th. Finally, N+1 Singer reaffirmed a buy rating on shares of Puretech Health PLC in a report on Monday, September 25th. Five research analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus target price of GBX 242.80 ($3.19).
Shares of Puretech Health PLC (LON PRTC) opened at GBX 125 ($1.64) on Monday. Puretech Health PLC has a fifty-two week low of GBX 110 ($1.45) and a fifty-two week high of GBX 139 ($1.83).
About Puretech Health PLC
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related companies with our FREE daily email newsletter.